Detection of LADA in a Hospital in the Mexican Southeast

Detection of Latent Autoimmune Diabetes in Adults, Clinical and Metabolic Profile in Patients Treated at the Diabetes Clinic in a Hospital in the Mexican Southeast.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05235672

Acronym

LADA patients

Enrollment

110

Registered

2022-02-11

Start date

2021-01-30

Completion date

2021-12-30

Last updated

2022-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent Autoimmune Diabetes

Keywords

LADA, GADA, Mexican population

Brief summary

Patients with Latent Autoimmune Diabetes in Adults (LADA) show autoantibodies that indicate an autoimmune pathogenesis. Glutamic acid decarboxylase autoantibodies (GADA) are most prevalent islet autoantibodies in European patients with LADA. In this sense, it is considered that it is sufficient to determine GADA to identify subjects with LADA from patients with T2D for research purposes. Therefore, the aim was to investigated the presence of GADA in serum of subjects with T2D and its relationship with clinical criteria, metabolic control, drug treatment, and diabetes complications to identify possible patients with LADA in a hospital in southeastern Mexico is worthwhile. The sample was recruited at the Diabetes Clinic of the Regional Hospital of High Specialty Dr. Gustavo A. Rovirosa Pérez, in the period from January 2020 to May 2021. The diagnosis was based in accordance with World Health Organization (WHO, 1999) criteria. Inclusion criteria: 1) patients previously diagnosed with T2D, 2) absence of insulin requirement for at least 6 months after diagnosis, 3) \> 30 and \< 50 years old at diabetes diagnosis, 4) BMI \< 40 kg/m2, 5) subjects who agreed to participate in the study and signed the informed consent before the interview. Serum GADA and other biochemical concentrations were determined by an enzymatic immunoassay method (Human Anti-Glutamic Acid Decarboxylase ELISA Kit; MyBioSource).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 50 Years

Healthy volunteers

Inclusion criteria

* patients previously diagnosed with T2D, * absence of insulin requirement for at least 6 months after diagnosis, * \> 30 and \< 50 years old at diabetes diagnosis, * BMI \< 40 kg/m2, * subjects who agreed to participate in the study and signed the informed consent before the interview.

Exclusion criteria

• patients with other types of diabetes, and subjects who did not agree to participate.

Design outcomes

Primary

Measure	Time frame	Description
GADA in serum of subjects with T2D	May 2021	Serum GADA concentrations were determined by an enzymatic immunoassay method in subjects with T2D

Countries

Mexico

Outcome results